Principal investigator
Takhar Kasumov, Ph.D.
Associate Professor, Department of Pharmaceutical Sciences
Contact
4209 St. Rt. 44, PO Box 95
NEOMED, RGE 432
Department of Pharmaceutical Sciences
Rootstown, OH 44272
College of Pharmacy
Department of Pharmaceutical Sciences

Takhar Kasumov, Ph.D.
Associate Professor, Department of Pharmaceutical Sciences
4209 St. Rt. 44, PO Box 95
NEOMED, RGE 432
Department of Pharmaceutical Sciences
Rootstown, OH 44272
Kasumov’s laboratory applies high-throughput unbiased system biology approaches, i.e. metabolomics, proteomics, and fluxomic to understand the pathogenesis of metabolic disorders, including alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD) and diabetes, and their cardiovascular and neurodegenerative complications.
Our current projects include:
Mechanisms of alcohol-induced liver injury: Alcoholic liver disease (ALD) is a major cause of liver-related death. There is growing evidence that the dysfunction of mitochondria (the part of the cell that converts food into energy) plays a key role in disease propagation. Alcohol intake is associated with hyperacetylation of hepatic mitochondrial proteins. This project studies the role of alcohol-induced changes in acetylome dynamics in mitochondrial dysfunction. The rationale is that hepatic mitochondria may respond to alcohol-induced stress via acetyl-transfer dependent enzymatic inhibition and/or the regulation of protein stability via acetylation. To assess the impact of these acetylation-mediated changes, we will quantify mitochondrial acetylome dynamics in ALD mice liver in vivo using a stable isotope-resolved high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Methods of temporal and spatial acetylome dynamics: Dysregulated post-translational protein acetylation at the lysine side chain by acetyl-CoA plays a critical role in the pathogenesis of various diseases, such as cancer, neurodegeneration, and metabolic disorders. In addition to modulating metabolic processes by affecting transcription and enzyme activity, acetylation regulates multiple facets of proteostasis, including protein stability. However, the lack of suitable techniques for studying acetylation dynamics in vivo poses a significant obstacle in developing effective therapies for acetylation-related disorders. To overcome this limitation, we are developing innovative techniques to accurately measure the rates of acetylation and deacetylation, as well as the effect of acetylation on protein stability in different organs and cell compartments. To achieve these goals, we will be leveraging the advancements of our 2H2O-based proteome dynamics method in conjunction with ultra-high-resolution Orbitrap mass spectrometer.
Acetylome dynamics in NAFLD: Protein acetylation links nutrient metabolism and enzymes involved in this process through reversible acetylation of proteins by acetyl-CoA, a key node in nutrient metabolism. In addition to acetyl-CoA availability, acetylation of proteins is regulated by adenine dinucleotide (NAD+), the redox cofactor and a substrate for family deacetylase sirtuins, including mitochondrial Sirt3. The objective of this project is to assess the mechanisms linking diet-induced dysregulated acetylation and altered substrate metabolism. We will quantify acetylation dynamics, and the role of acetylation on mitochondrial protein stability in Sirt3-/- mice characterized by hepatic mitochondrial hyperacetylation. Then, we will use this method to assess the role of acetylation in hepatic substrate metabolism in a high-fat diet (HFD)-induced mouse model of NAFLD.
Type 2 Diabetes and Preclinical Alzheimer’s Disease: Diabetes-related cardiovascular risk factors have been associated to higher risk of dementia and Alzheimer’s Disease (AD) in late life. The large number of younger diabetics among both the general population and veterans is vulnerable to a significant future risk of dementia. T2DM is associated with systemic metabolic changes including low levels of HDL cholesterol and ApoA1, the major protein of HDL involved in reverse cholesterol transport function of HDL. Our preliminary study in T2DM patients shows that glycation of plasma ApoA1 results in reduced stability of ApoA1 and inefficient cholesterol transport function of HDL. Dr. Pillai, our collaborator from Cleveland Clinic, observed that baseline plasma ApoA1 levels are associated with poorer memory scores and CSF baseline ApoA1 levels predicts future cognitive decline among cognitively normal subjects. In collaboration with Dr. Pillai, we will evaluate the relationship between plasma ApoA1 (total and glycated) and CSF biomarkers related to cognition.
See open positions in this lab on the NEOMED careers site

Q Exactive Plus Orbitrap (Thermo Scientific)
Q Exactive Plus with normal flow and nano-flow chromatographic inlet offers untargeted metabolomics and proteomics studies. High resolution (up to 140,000), accurate mass (<1ppm) HRAM) and full-scan capabilities captures all sample data at all time points with confidence when analyzing samples in complex matrices. Selected ion monitoring (SIM) and parallel reaction monitoring (PRM) enables targeted analysis of hundreds of metabolites and peptides levels with high specificity and sensitivity. High resolving power eliminates isobaric interferences, increasing the sensitivity of metabolic flux and dynamic proteomics studies. Mass range to 6,000m/z enhances detection of singly charged small molecules and biomolecules. More than four orders of magnitude dynamic range, along with femtogram-level sensitivity, allow detection of trace-level and high-abundance compounds in the same scan.
GC-MS (Agilent)
This capillary gas chromatography coupled with a single quadrupole mass spectrometer is designated for the direct analyses of volatile small molecules or derivatized compounds. The electron ionization (EI) on this instrument induces fragmentation in the source and produces characteristic mass spectra that can be searched against the EI spectra library. Although the MassHunter software coupled with NIST library allows non-targeted metabolic profiling, the GC-MS instrument is best suited for the targeted metabolomics and stable isotope-based flux studies.
Serguei Ilchenko, Ph.D., research scientist
Victor Lufi, B.S., research technician
Andrea Aras-Alvarado, M.D., Ph.D. candidate
Mirjavid Aghayev, M.S., Ph.D. candidate
Cheri Harris
Business Manager
Phone: 330.325.6689
Email: charris1@380cebbe0d.nxcli.io
Moses Oyewumi, Ph.D.
Phone: 330.325.6669
Email: moyewumi@380cebbe0d.nxcli.io
© 2024 Northeast Ohio Medical University
4209 St. Rt. 44, PO Box 95, Rootstown, Ohio 44272
ADA compliance | Consumer information | Title IX | Privacy statement | Do business with NEOMED